Testing Follow-Up Treatment After Surgery for Cervical Cancer Using Residual Disease Screening
Tests chemoradiotherapy with zimberelimab after surgery in adults with cervical cancer at risk.
Plain-language title generated from the registry record
Registry title: Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
Key facts
- Where
- Suzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with early cervical cancer, stage IB2 to IIA2, who are having treatment after surgery.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Cervical cancer, FIGO 2018 stage IB2 to IIA2, confirmed by tissue tests and clinical examination
- Earlier treatment
- The record names only treatment after surgery (chemoradiotherapy with or without Zimberelimab). It sets no required earlier treatment.
Main reasons for not taking part
- Another cancer
- An autoimmune disease
- Cannot follow the planned treatment or follow-up schedule
- Cannot have CT or other planned check-up tests
Read by machine on 9 November 2026.
Where in China
- The Affiliated Suzhou Hospital of Nanjing Medical UniversitySuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Suzhou Municipal Hospital
- Trial code
- NCT05872724
- Record updated
- 24 May 2023
- Original description
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.Read full original descriptionShow less
Clinical Study on Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD
This study is a prospective cohort clinical trial that aims to investigate the safety and efficacy of a combined chemoradiotherapy and immunotherapy treatment for early postoperative cervical cancer. Specifically, this study seeks to evaluate the ability of MRD-based screening to detect and monitor changes in MRD status at different stages of treatment, its potential for use in monitoring patient recurrence rates and in prognosis evaluation. In addition, this study will investigate the safety and effectiveness of chemoradiotherapy combined with immunotherapy as a postoperative adjuvant therapy for patients identified to be at risk of early cervical cancer based on MRD screening.
Inclusion: Patients with histopathological and clinical (FIGO 2018) stage ⅠB2 ~II A2 cervical cancer; Above the age of 18; General status: ECOG score 0-2; Be able to understand the research scheme, voluntarily participate in the study, and sign the informed consent; Good compliance, able to cooperate with the collection of specimens at each node and provide corresponding clinical information.
Exclusion: Suffering from other malignant tumors; Do not receive the specified treatment or change the treatment regimen before the disease progresses; Have an autoimmune disease; The study cannot be followed up according to the defined clinical follow-up period; Unable to accept or provide CT or other designated therapeutic evaluation means.